NEW YORK (GenomeWeb News) – Celsis In Vitro Technologies, a division of life science products and lab services firm Celsis International, today announced that it is collaborating with Promega on ADME-Tox assays for hepatocytes.

Baltimore-based Celsis IVT said that it will provide pre-qualified lots of its cryopreserved hepatocytes for use with Promega's bioluminescent ADME-Tox assays, including those used to study cytochrome P450 gene induction and inhibition and its GSH-Glo Glutathione assay for investigating mechanisms of hepatoxicity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.